Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
93 participants
OBSERVATIONAL
2007-02-28
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients are included in the French perinatal cohort (ANRS CO-10), or have been followed since before 1996 in the same clinical sites as patients who belong to ANRS CO-10. In the ANRS CO-10 cohort, all patients are prospectively followed from birth.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Efficient anti-retroviral treatments lead to a significantly increased life expectancy. Children with perinatal infection are now reaching adulthood. The deleterious impact of viral replication during ontogenesis of the immune system, and the high thymic activity during the early years of life, preclude an extrapolation from data pertaining to the adult immune status and mean that specific pediatric studies are required. No data are available concerning the immune status of adolescents or young adults infected via materno-foetal transmission.
Detailed description:
Our assumption is that the duration of uncontrolled viral replication will affect the immune status after treatment because viral replication is associated with:
1. disease progression independently of CD4+ T cell levels;
2. accelerated senescence of the immune system;
3. destruction of organs involved in the restoration of major immune cell populations.
The aims of the study are:
1. to describe the immune and virological status of perinatally infected patients that are above 15 yrs old and
2. to study their associations with :
1. the current virological/clinical and therapeutic status,
2. the duration of uncontrolled viremia (defined by treatment history),
3. the virological, immunological (CD4+ numbers), and clinical status at time of HAART initiation.
The immune status will be defined by (1) the number and phenotype of CD4+ and CD8+ T lymphocytes, dendritic cells, regulatory T cells, and NK cells, (2) the functions (proliferation and cytokine production) of CD4+ and CD8+ lymphocytes that are specific for HIV, a recall antigen (tetanus toxoid) and other viruses (CMV, EBV and Flu),the repertoire of Natural Killer cell receptors.
The virological status will be defined by the level of HIV DNA in PBMCs, the HIV subtype, resistance mutations in archived and circulating virus and sequences of the regions of the viral envelope involved in co-receptor use.
Clinical, therapeutic, demographic, virological and immunological data are collected from birth for members of the ANRS CO-10 cohort, and will be collected retrospectively since diagnosis for non-included patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A single blood sample (30 mL)
A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being followed in the Paris area
* HIV-1 infected through the perinatal route, and not HIV-2 co-infected
* No therapeutic changes for at least 6 months; single molecule change without modification of viral load is tolerated.
* Informed consent signed by the patients and by their legal guardians for those younger than 18.
Exclusion Criteria
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Pasteur
INDUSTRY
University of Paris 5 - Rene Descartes
OTHER
Hôpital Necker-Enfants Malades
OTHER
French National Agency for Research on AIDS and Viral Hepatitis
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
French National Agency for Research on AIDS and Viral Hepatitis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Warszawski MD Josiane, Methodologist
Role: STUDY_CHAIR
INSERM U 822, Hôpital de Bicêtre, portes 10 à 15, 82 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre Cedex [email protected] ; Tel : 01 45 21 22 86
Blanche PHD Stéphane
Role: PRINCIPAL_INVESTIGATOR
Hopital Necker Enfants malades-Service immunologie hématologie pédiatrique -149 rue de Sèvres- 75015 PARIS 01 44 49 48 24
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Riviere Y, Warszawski J, Rouzioux C, Buseyne F. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis. 2012 May 15;205(10):1520-8. doi: 10.1093/infdis/jis233. Epub 2012 Mar 15.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-AO142-49
Identifier Type: -
Identifier Source: org_study_id